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Abstract
Background: Benzodiazepine withdrawal syndrome has been reported following attempts to withdraw even from
low or therapeutic doses and has been compared to barbiturate and alcohol withdrawal. This experience is known
to deter patients from future cessation attempts. Research on other psychotropic substances shows that the reasons
and motivations for withdrawal attempts – as well as the experiences surrounding those attempts – at least partially
predict future efforts at discontinuation as well as relapse. We therefore aimed to qualitatively explore what motivates
patients to discontinue this medication as well as to examine their experiences surrounding previous and current
withdrawal attempts and treatment interventions in order to positively influence future help-seeking behavior and
compliance.
Methods: To understand these patients better, we conducted a series of 41 unstructured, narrative, in-depth interviews
among adult Swiss patients with a long-term dependent use of benzodiazepines in doses equivalent to more than
40 mg diazepam per day and/or otherwise problematic use (mixing benzodiazepines, escalating dosage, recreational
use or illegal purchase). Mayring’s qualitative content analysis was used to evaluate findings.
Results: These high-dose benzodiazepine-dependent patients decision to change consumption patterns were affected
by health concerns, the feeling of being addicted and social factors. Discontinuation attempts were frequent and not
very successful with fast relapse. Withdrawal was perceived to be a difficult, complicated, and highly unpredictable
process. The first attempt at withdrawal occurred at home and typically felt better than at the clinic. Inpatient treatment
was believed to be more effective with long term treatment (approaches) than short term.
Patients preferred gradual reduction of usage to abrupt cessation (and had experienced both). While no clear
preferences for withdrawal were found for benzodiazepines with specific pharmacokinetic properties, participants
frequently based their decision to participate in treatment on the availability of their preferred brand name and
furthermore discarding equivalent dosage rationales.
Conclusions: Our findings provide greater understanding of the factors that motivate high-dose benzodiazepine-
dependent individuals to stop taking these medications, and how they experience withdrawal and treatment strategies.
They underscore how patients’ perceptions of treatment approaches contribute to compliant or non-compliant behavior.
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Background
Benzodiazepines (BZD) are a highly effective psycho-
active drug with anxiolytic, hypnotic, muscle-relaxant,
and anticonvulsant properties. They are most commonly
used to treat symptoms of anxiety and insomnia [1-3].
Adverse effects most notably include cognitive and psy-
chomotor impairments, as well as dependence after con-
tinuous and/or long-term use [4-6]. Prevalence rates for
long-term use among BZD users are estimated to be be-
tween 25-76% [7]. Furthermore, some 20 - 50% of BZD
users are believed to experience some sort of withdrawal
when trying to discontinue BZD after extended use, in-
dicating signs of dependence [8,9]. While most long-
term BZD users do not escalate dosage after reaching a
saturation level, and remain within recommended dos-
age regimens, some patients develop high-dose depend-
ence. Prevalence of this form of BZD dependence is
difficult to estimate, but a cross-sectional study of the
Swiss population found that 1.6% of patients with long-
term use of BZDs (n = 25 354) received prescriptions ex-
ceeding recommended dosage by at least two times [10].
Matters are further complicated by a heterogeneous use
of the term within the scientific community: Some au-
thors differentiate between high-dose dependence that
results from long-term prescription abuse following
treatment of an underlying condition, and high-dose de-
pendence that is a consequence of BZD use for recre-
ational purposes (e.g., enhancing the effects of other
drugs or reducing withdrawal symptoms, etc.) [11,12].
Regardless of group differences, however, high-dose BZD
users are believed to suffer more frequently from comor-
bid mental disorders, might not sustainably benefit from
current discontinuation and withdrawal strategies, and
are thus exposed to an increased risk of impairment and
injury [13-16]. Benzodiazepine withdrawal syndrome has
been reported following attempts to withdraw even from
low or therapeutic doses [12,17], and has been compared
to barbiturate and alcohol withdrawal [18-20]. It has also
repeatedly been associated with symptoms that can
range from anxiety, panic attacks, sleep disorders, cog-
nitive impairments, and muscle spasms, to perceptual
hypersensitivity, depersonalization, hallucinations, excit-
ability, symptoms of psychosis, and convulsions [20,21].
While the perceived severity of these symptoms has
been linked to long-term and high-dose BZD use, fast-
onset and short-acting BZDs, and anxious personality
traits, it occurs very frequently, with an incidence of
30-100% (not taking into account the 50% of long-term
BZD users who have been reported not to consent
to withdrawal studies or to later pull out of them)
[12,22,23]. Furthermore, the experience of withdrawal
is known to deter patients from future cessation at-
tempts. Accordingly, some researchers have called for
investigation of long-term and/or high-dose users
in relation to evaluating discontinuation of treatment
[15,24,25].
Research on other psychotropic substances shows that
the reasons and motivations for withdrawal attempts—as
well as the experiences surrounding those attempts—at
least partially predict future efforts at discontinuation, as
well as relapse [26,27]. We therefore aimed to qualita-
tively explore these clinical questions within a sample of
high-dose BZD-dependent patients to better understand
patients’ perceptions of current treatment interventions.
Methods
Study design
To elucidate high-dose BZD users’ reasons and motiva-
tions for withdrawing from these medications, and their
view of previous BZD withdrawal attempts, the authors
conducted an exploratory qualitative study. For the
study, only users who took BZDs for an extended period
of time, for a dose equivalent to more than 40 mg diaze-
pam per day, and/or those who had an otherwise prob-
lematic use of BZDs (such as mixing BZDs, escalating
their dosage, using BZDs for recreational purposes, or
obtaining BZDs by illegal means), were invited to partici-
pate. A series of 41 unstructured, in-depth interviews
lasting for about 60–90 minutes were conducted by inter-
viewers who had previous experience with one-on-one
qualitative procedures and the treatment of substance-
abusing individuals. All participants were assured com-
plete confidentiality and provided their written informed
consent, specifically to the digital recordings of the inter-
views. Zurich’s cantonal ethics committee approved this
study.
Participants
Patients who presented to the in- or out-patient units of
the Psychiatric University Hospital Zurich between 2011
and 2012 with a diagnosis of high-dose BZD dependence
(according to ICD-10), and who were at least 18 years of
age and willing to give written informed consent, were
invited to participate in the interviews. Exclusion criteria
were defined as vastly insufficient language skills and
acute intoxication. The full chart of each patient was
made available by the clinic, including a complete
biographical and psychiatric history and the patient’s
diagnosis according to ICD-10. The members of our re-
search group approached potential participants, who
were identified by treating physicians. Interviews were
then conducted outside the regular treatment setting to
further ensure that participants freely expressed their
own views and perceptions. They were assured that no
information from the interviews would be given to treat-
ment providers. Incentives were provided to both in-
patient and outpatient subjects for their participation
into the study.
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Sample
A mixed method of purposeful sampling and saturation
sampling principles was used. To achieve greater vari-
ation of themes and motives, we recruited subjects from
both general treatment settings and from units specializ-
ing in the treatment of substance- use disorders. The
sample was also selected to provide diversity in relation
to: (1) comorbidity and past clinical experience, (2) dur-
ation of high-dose-benzodiazpine use, (3) gender (m/f),
(3) age and (4) occupational status. Recruitment of par-
ticipants continued until saturation of data was reached.
In total sixty particpants were contacted. Forty-one agreed
to participate. Obstacles to study participation were sel-
dom addressed by potential participants. Fourteen partici-
pants left the impression of being too ashamed to talk
about the subject. Only in two instances did participants
decline to participate because they perceived the amount
of compensation (approximately the equivalent of USD 5)
as inadequate. In three cases, potential participants agreed
to be interviewed, but withdrew their consent during the
interview – naming a lack of interest in the research topic.
Interview
In accordance with recommended principles of conduct-
ing qualitative research, the interview began with narra-
tive opening questions; however, a self-developed topic
guide (vide infra) provided a flexible interview frame-
work to explore beliefs that were not spontaneously cov-
ered in participants’ initial narrative. Special care was
given to ask open-ended and neutrally worded questions
to avoid eliciting socially desirable responses. In addition,
appropriate nonjudgmental and non-leading probes were
used to explore perceptions that were raised spontan-
eously by in patients’ initial narratives. We allowed the
themes and motives identified in earlier interviews to be
explored in the ones that followed, and combined the
principles of maximum variation and complexity reduc-
tion to simultaneously widen the scope of results and
examine previous assumptions.
Data analyses
Data collection and analyses were conducted simultan-
eously until saturation had been reached. All interviews
were conducted in Swiss German (an Alemanic dialect
spoken in the “German-Speaking” parts of Switzeralnd)
digitally recorded, using dictamus for iOS, and then
transcribed verbatim into Standard-German, since Swiss
German is not a “written language”. Potentially identify-
ing information was removed and transcripts were
assigned a code number. Mayring’s qualitative content
analysis approach was used to evaluate findings [28].
This framework constitutes a controlled approach for
empirical and methodological qualitative analysis. Instead
of approaching the data with preconceived assumptions,
the data were allowed to “speak for themselves.” Mate-
rials were coded using an inductive qualitative procedure.
Categories obtained were discussed by the research team
to validate ratings and achieve consensus on a biweekly
basis. ML applied the final code, with confirmation of
consistency through blind dual coding of transcripts with
MG and CC. All researchers applying the codes had re-
ceived training either as psychologist or as psychiatrists
and had previous research experience with qualitative
methods [29,30].
Results
A total of 41 participants were interviewed. One partici-
pant passed away after having completed the interview
(and having given informed consent) thus data were still
included. Table 1 shows the clinical and sociodemographic
features of the sample. Data presented are predominantly
self reported (employment status, benzodiazepine use pro-
file) supplemented and objectified with information from
individual patient charts (current medication, ICD-10
diagnosis). The mean duration of benzodiazepine use was
8.2 years +/− SD 6.82 (median 5.0 years) with a mean di-
azepam equivalent dosage of 83 mg +/− SD 69 (median
70 mg). Participants with a high-dose benzodiazepine de-
pendence according to our inclusion criteria, had a high
probability of carrying at least one (36.6%) or more (39.0%)
lifetime psychiatric diagnoses according to ICD-10. 21
(52%) participants had a past or current affective disorder
(ICD-10 F3), followed in frequency by personality disor-
ders (ICD-10 F6) in 34.1% and neurotic, stress-related and
somatoform disorders (ICD-10 F4) 29.3%. Only a minority
of subjects (9.8%) had experiences with no other psy-
chotropic substances than benzodiazepines. The majority
reported a past or current use of one (19.5%) or more
(70.7%) substances, most frequently citing heroin (68%), al-
cohol (63%) and cocaine (53.6%). The heterogeneity of this
sample is further underscored by its employment status:
While 29.3% were employed at the time of the interview,
26.8% were not and 39% were recipients of a disability
pension. Type of labor varied greatly between unskilled
(exotic dancer), semiskilled (housepainter, bus driver) and
skilled work (welder, nurse, cook, social worker).
Participants’ reasons and motivations for withdrawing
from benzodiazepines
Subjects discussed a variety of reasons why they wanted
to withdraw from BZDs. But it was interesting that they
generally addressed this topic only after they were spe-
cifically asked to; they often perceived the wish to stop
as self-explanatory and without need of further elucida-
tion. The process that led participants to decide to stop
taking BZDs was found to involve a multifaceted inter-
action of different factors. We identified three major
themes that were important in affecting the decisions of
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patients to change their consumption patterns: (1) con-
cern about health, (2) the feeling of being addicted, and
(3) external social factors.
Concern about health
The primary reported motivation to discontinue BZD
use was concern about health. Participants were typically
afraid of serious cognitive and physical impairments if
they continued use.
“And I am now 34 and have read in the Internet that
they (BZDs) destroy internal organs, and that it can
have devastating consequences when you are taking
them for a long time.”
VP_04
Commonly, subjects drew upon their own experience
with the substance and said that they felt they had no-
ticed deterioration of their memory after extended use.
“I actually wanted to stop it for a long time, when I
noticed that I developed problems with my short-term
memory…”
VP_17
“You are getting a little dumb. You are doing things
that you later regret. I, for example, was cheating on
my boyfriend while I was using Dormicum®
(midazolam). And then I got pregnant and had to
have an abortion, just because I was using that.”
VP_37
Participants often noticed these subjective memory im-
pairments in their performance of daily tasks, which heavily
influenced their decision to change consumption patterns.
“I have stopped cooking at home because I forgot so
many things, and then it was just burned. Then my
children prohibited me to cook. They are anyway all
day in the University, and eat there.”
VP_33
In addition, some participants reported that although
they did not share the view that their chronic and high-
dose BZD use had negative effects on them, they had
heard dramatic descriptions from colleagues or physicians
about the consequences of such consumption patterns. In
this context, a number of subjects stated that they had
witnessed other people’s inpatient withdrawal attempts
and had found them so disturbing that this in itself had
contributed to their decision to stop using BZDs.
“I think from a rational thinking perspective it affected
my brain not very much…but I have talked to people
Table 1 Clinical and sociodemographic features of the
sample
n %
Number of participants 41
Gender
Male 31 75.6
Female 10 24.4
Duration of use
<5 years 14 34.1
5-9 years 12 29.3
>10 years 14 34.1
Could not recall 1 2.4
Age of onset
<25 15 36.6
25-39 18 43.9
>40 7 17.1
Could not recall 1 2.4
Employment status
Employed 12 29.3
Not employed 11 26.8
Retired 1 2.4
Disability pension 16 39.0
No data 1 2.4
Diazepam equivalent dosages
<50 mg 14 34.1
50-99 mg 14 34.1
>100 mg 13 31.7
Lifetime substance use except
for benzodiazepines
None 4 9.8
One 8 19.5
More than one 29 70.7
Number of comorbid psychiatric
diagnosis groups except substance
use disorders (F2, F3, F4, F6, F9)
None 10 24.4
One 15 36.6
More than one 16 39.0
Comorbid psychiatric diagnosis
groups except substanc use disorders
F2 1 2.4
F3 21 51.2
F4 12 29.3
F6 14 34.1
F9 1 2.4
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who have been taking benzos for 10 or 20 years and
they tell you about headaches and this and that. That
is something that scared me.”
VP_34
“My doctor told me that you can develop a dementia
from it and I don’t want to get demented.”
VP_29
Only a few participants felt that using BZDs had nega-
tively affected their mood and resulted in a loss of energy,
citing this reason as a main factor in their wish to stop.
“I decided for a withdrawal, because during the last
couple of weeks and months they really pulled me
down and I had not leisure time activity any more,
because I just took a bunch of benzos in the morning.
It took the form that I lost my momentum.”
VP_25
Two individuals reported that they were brought by
ambulance to the emergency room and had later been
stabilized at the hospital. These individuals perceived
that live-threating events had caused them to consent to
transfer to an inpatient psychiatric unit, and had mo-
tived them to undertake withdrawal.
“They (ambulance) had to come and get me at home
on an emergency basis. It took four days in the
hospital to bring me back to life and then I decided to
come here (to the inpatient psychiatric unit).”
VP_02
The feeling of being addicted
Another motivational factor for many participants was
the feeling of being addicted and/or dependent on a psy-
chotropic substance.
“…and then I someday I noticed that I woke up in the
morning and was already thinking about where to get
Dormicum® (midazolam), and I understood during the
last months, that I could not continue like that, that I
had to decrease the use.”
VP_22
Explanatory models with a strong moral connotation
often accompanied this motive:
“You have to prioritize in life what is important and
what is not. I think it is very important in life not be
dependent on anything, or on a pharmaceutical drug for
that matter, but once you have started you have entered
a vicious circle and it is difficult to get out of it.”
VP_04
“It is almost like being in love. Blindly. When you are
in love you are blinded too. You are in love with this
drug… I have not needed it before, why do I need it
now. So, get rid of it!”
VP_35
For less abstract reasons, participants perceived their
high-dose dependence as limiting their freedom of
movement, both in relation to traveling and to having
the leeway to spontaneously make or change plans.
Participants who had a history of/or a current comor-
bid heroin use often drew comparisons to opioid de-
pendence; some of them linked abstinence goals for
BZD use with a desire to terminate opioid maintenance
treatment, as well.
“Because it is crap, when you want to go into a foreign
country, you have to take a package (of tablets) with
you, and in some countries, they can act really stupid.
It is the same with Methadone.You have to have a
letter from your physician with you, but then it is all
right. In Europe it is generally not a problem.”
VP_07
“It is the same like being heroin addicted, I build my
own prison, I can not spontaneously decide what I
want to do, where I want to go… I always have to
check that I have enough drugs on me…”
VP_13
One participant reported to have attempted BZD with-
drawal out of interest in the results and to evaluate his
competence without this drug.
“And I asked myself, if I wanted to withdraw BZDs
and see for myself If I can handle (social and business
pressures) without using them.”
VP_19
Relevance of social and interpersonal factors
A major source of motivation to cease the BZD use resulted
from external social factors. Participants who were inter-
viewed during an inpatient withdrawal attempt most com-
monly mentioned this motive; and others said that their
immediate family members, relatives, and significant others
were often frustrated with them for using BZDs. Thus, ex-
ternal and interpersonal factors were cited as an important
motivational influence for discontinuing BZD use.
“And then my girlfriend told me that I was not myself
yesterday, that I was a different kind of human being. And
that I could not change. And that really hurt my feelings.
And then I told myself: “I will not take benzos anymore!”
VP_14
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“I was really stressing out my family, because I forgot
what they have told me and then I asked the same
questions again and then they told me: ‘You have
asked twice already, or we have told you yesterday…’”
VP_28
Within this context, participants said that they either
wanted to please their partners because they themselves
believed that their BZD use had a negative effect on
their social interactions, or that they forced themselves
to participate socially because they were told by people
related to them that they would end the relationship if
the subject did not seek treatment.
“It became very problematic lately. My wife always told
me: ‘You forget everything, I tell you something and you
forget it.’And early this year she told me: ‘It does not
work like this. If it goes on like this, you will be so far
down, that you will not find home one day. And she told
me, ‘If you stay like this, then you are disturbed, then I
will leave you and take the child. You have to go into
the hospital.’And I think she is right.”
VP_08
Since participants were often unaware of their erratic
behavior, they were sometimes video-filmed with mobile
devices to make it possible for family members or col-
leagues to confront them. Participants often experienced
these showings as very shameful.
“And then of course I ran into problems with my
girlfriend. I came home sedated, always, falling asleep
at the table. She was ashamed of me when we went to
have dinner in a restaurant. I had hooded eyes, my
head on the plate. But I had the impression, that I
was all right, that I was normal and I was asking
what kind of problems other people had with me… She
then took pictures of me with the cellular phone and
showed them to me when I was still sober the next
morning. I could not believe it. That could not be me. I
was shocked. Really. Terrible.”
VP_30
On a different note, it became apparent that many par-
ticipants were also under enormous institutional pres-
sure to suspend BZD consumption They commonly
reported that living facilities intended to terminate hous-
ing agreements in case they continued use of BZDs.
“…it was basically an obligation, a demand. I was told
that either I go for inpatient withdrawal or I will get
kicked out of the sheltered accommodation I live in… but
I would have gone anyway, it maybe a good thing to do…”
VP_26
Many participants with children thought that their
continued BZD use might negatively affect their parent-
ing abilities, and cited this as a factor in their motivation
to quit. One mother revealed that her children had been
placed into custody and that she was mandated to stop
using BZDs if she wanted to be with them again, while
another was afraid of this scenario.
“My children were taken from me. We wanted to enter a
mother-child facility, but they were not sure if I would
still be taking benzos. They told me that I could not
enter; initially I would have to get into a (psychiatric)
hospital, so that they would be sure I was not taking any
benzos. That is the most depressing thing: that my
children were taken and (placed into custody).”
VP_38
Other practical reasons to enter a withdrawal treatment
included potential loss of a driver’s license, anxiety over
losing disability compensation, financial considerations,
and/or physicians’ threat to stop prescribing BZDs.
“I am scared that the disability insurance will come
under a lot of pressure and that society will not
continue to show solidarity with ill people, maybe
because social thinking is vanishing. I hope that I am
wrong… I could imagine that mental disorders will be
taken out of the catalogue… This is one reason I want
to withdraw. Maybe this attempt will improve my
health status, and I have a very bad one, to the point
that I have a little chance on the job market… but I
am scared that without benzos, anxiety, depression,
and the obsessions will come back…”
VP_11
“…It is getting more expensive and I cannot find a doctor
who is prescribing it to me, and in the ZOKL (outpatient
treatment center) they don’t want to give it to me, either.
I think from his (physician’s) side it is legitimate… he did
not want to watch how I destroy myself…”
VP_34
Participants’ view on previous BZD withdrawal attempts –
symptoms, helpful strategies, and outcome
Participants’ experiences stopping BZD use were much
more heterogeneous, especially in relation to duration
and quality of symptoms. Despite this, we were able to
identify seven common motives and a number of re-
peated perceptions about quitting BZD use.
Withdrawal is frequent and not very successful
Most participants in this sample of high-dose dependent
patients reported multiple previous attempts to quit BZD
use. While treatment often resulted in a reduction of the
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amount of BZD used, and sometimes (self-proclaimed)
months or even years of abstinence, the majority of this
sample reported frequent relapse, typically after days or
weeks.
“I went a lot to my psychiatrist, to my general
practitioner, looking for a way that it would work for
me. But my doc tells me you can only do a withdrawal
attempt in the hospital. But I have been to this hospital
at least 20 times. It does not work. For example: I
withdraw in here, and leave for home. Then it is all
right for two or three months and then it starts again.”
VP_18
“I tried to stop five-six times by myself…
VP_12
Subjects who abused BZD in high doses and were also
dependent on other psychotropic substances usually dis-
tinguished between their attempts to withdraw from dif-
ferent kinds of drugs:
“So, like withdrawal, just benzos withdrawal? I went
six-seven times, and twice just because of benzos… ”
VP_24
Withdrawal is difficult, complicated, and unpredictable
None of our high-dose dependent study subjects de-
scribed cessation of BZD use as relatively easy or un-
accompanied by only minor complications. To the
contrary, the vast majority of participants regarded with-
drawal as highly stressful, accompanied by a wide variety
of symptoms whose onset and duration were difficult to
predict and ranged from days to months. Most often,
subjects compared withdrawal to an influenza infection:
they experienced chills, weakness, headache, muscle
pains, abdominal pain, nausea, vomiting, diarrhea, tachy-
cardia, dizziness, and vision disorders. Others reported
irritability, nervousness, restlessness, difficulty sleeping,
symptoms of depression and anxiety, tickling sensations,
dissociation, and a complete loss of appetite. Further-
more, subjects repeatedly described withdrawal-related
seizures that had left them very worried. Participants
who had also attempted withdrawal from opioids gener-
ally described stopping BZD use as a much more diffi-
cult task.
“I have experienced very bad withdrawal, it shook me
out of bed, I was twirling around, chill-shivering, ice
cold…”
VP_09
“…because if you stop it…ah…then comes the
withdrawal, then you cannot sleep anymore… and
when it gets really crazy is when you experience vision
difficulties… for example this sheet of paper… 1,
3 weeks ago I could not have read it.”
VP_10
“…Benzodiazepines can be really sinister. You take one
tablet less and you seem to do just fine for a week or two
and then comes crashing down a huge wave. In the end
I was for one week on zero Seresta® (oxazepam), but just
when I left (the hospital) the bad episodes hit…”
VP_16
“I had had extreme tickling in my legs. Especially when I
was lying down. It is just like heroin withdrawal… I was
screaming in pain. It is being said that (benzo
withdrawal) is like an influenza, just 10 times worse,
but an influenza is nothing in comparison…You can not
sleep and you are twitching the entire time. I must have
been screaming during the night, then they always
brought me a Temesta® (Lorazepam) 2.5 mg, then it got
better. It is really…you get scared of the blood in your
legs. You want to ligate them, or hit them. It is so bad
you can not describe it if you did not experience it
yourself. And than of course the twitching…”
VP_38
“…Many people say that BZD withdrawal is much
worse than methadone, for example. But I experienced
that differently… I was just shaking and had one
epileptic seizure after another…”
VP_05 (participant deceased)
The first time takes place at home
In this group, most subjects reported attempting an ini-
tial withdrawal either alone at home or with some col-
leagues. For the most part, these attempts were planned.
However, some subjects reported that they only became
aware of their dependence because they experienced
influenza-like symptoms and were told by other people
that these symptoms might be associated with ending
their use of BZDs. It is not surprising that these initial
attempts were usually conducted without consulting a
physician and without pharmaceutical support; users
abruptly stopped taking the drug. Results varied. Some
participants experienced symptoms so severe that they
sought medical help within days, while others reported
epileptic seizures but still considered abrupt withdrawal
a very effective form of treatment.
“Yes, and then I made this withdrawal. And I made it
alone and I made it! I was laying in bed for three days
nauseous, vomiting and with diarrhea, and then
finished…”
VP_01
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“When I did the withdrawal at home, there were days
when you could not leave the house because you were
shaking so strongly, so you just stayed in.”
VP_15
“And then I stopped from one day to the other, alone, at
home, my husband was working back then. On the first
day, I did not notice anything; on the second day,
neither. But on the third day it started with shaking,
nausea, in the beginning just light. I told myself that I
can bear this, it would pass and I did not go to my
psychiatrist, I told myself, I will handle this alone. This
went on for two weeks and at the end of the second week
I could not eat, nor drink, nor sleep nor do anything. I
could not sit still and was running all the time through
the apartment…and finally I could not bear it any
longer and I went to see my psychiatrist.”
VP_12
“Then I thought, all right, today I will not take any
benzodiazepines and wop…I noticed that I felt
withdrawal, nervousness, shivers. And soon I figured I
should do my first withdrawal attempt, Rohypnol®
(flunitrazepam) withdrawal for that matter and had
immediately my first epileptic seizure. And I
immediately broke my nose… (A seizure) is something I
did not have before. But since then I had a lot of
seizures, mostly when I don’t take anything…”
VP_27
“…Ahh, and I did one benzo withdrawal with a friend
of mine and my mother in Italy. My physician did not
give me anything, but his doctor gave us tablets for the
two of us. We went with 900 mg down there and had
a party the first night. I had six packages with me,
and I thought I will need that…”
VP_27
At home feels better than in the clinic, but inpatient
treatment is more effective
Participants expressed a clear preference for treatment
approaches in an outpatient setting because they wanted
to remain in their communities. However, they fre-
quently pointed out that they did not manage to take
their medication as prescribed when they were in the
process of slowly decreasing. This often led to a decision
to enter inpatient treatment—which was perceived as
limiting personal freedom but was also considered faster
and more effective because they found that BZD dosage
was reduced more quickly in a hospital setting.
“The entire withdrawal will probably take two-three
weeks and until now it is good. I feel nothing. Actually
I do not want to be here…and my psychiatrist wanted
to send me here, but I did not want to leave my hus-
band nor my dog alone, did not want to leave my
home until it was almost too late…”
VP_12
“…I tried to reduce in an outpatient setting, but I did not
make it, and that is when I said, ‘All right, I will enter
the psychiatric hospital voluntarily for the withdrawal.
But today it is a catastrophe, because it is too fast for my
perception; we are reducing every other day…’”
VP_28
“Then you want to withdraw outside, but you don’t
make it, because you start missing things (tablets). I
think if it were close by, and I could receive the tablets
just for each day, then I could get a better handle for
it, as if I receive it for a week… it took a little time, but
now I am here (inpatient unit).”
VP_34
“…My psychiatrist first wanted to do it in an outpatient
setting, but that takes too long of a time because you
have to reduce little by little dosages and that very
slowly. But I have two little children at home, and I
either function somehow or I am just out of the picture.
It just does not work that I sit at home for three-quarters
of a year. I knew what I was getting into. That is why I
decided not for outpatient but for inpatient treatment.
Better in the hospital, short and to the point…”
VP_41
Gradual tapering is better than abrupt cessation, and few
other things help
Participants tended to compare their different with-
drawal experiences, and said it was easier to slowly re-
duce an administered dosage of BZDs. They expressed
no clear preferences for BZDs with specific pharmacoki-
netic properties, but they did feel passionate about this
subject and often extensively elucidated what worked for
them. Because some participants had had favorable or
unfavorable experiences with different brand names,
they based their decision to participate in treatment on
the availability of their preferred substance. These incli-
nations were not only highly subjective and often did
not take into account equivalent dosage rationales—they
also seemed sometimes to be uncorrectable by their phy-
sicians. Participants who mixed different BZDs consid-
ered the first days of treatment, and the search for an
initial dose to taper from, as the most difficult part. Gen-
erally, subjects viewed neuroleptics as ineffective; and
alternative, non-pharmaceutical approaches were rarely
mentioned.
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“I had 12 mg Xanax® (alprazolam) a day, an
incredible dosage. Over the period of one, one-and-a-
half years, we weaned off it until zero…”
VP_29
“I am feeling very well. I did not make the same
mistake like last time. That time I was reducing too
swiftly, in the same time of two weeks I had already
reduced by two tablets. That was too much…”
VP_16
“…when I see it is a good time to reduce the BZD
dosage, then I will go down, but certainly not abruptly,
fastly. I have done that in the past a lot, also with
Methadone, and it then often proved to be
counterproductive, that I took after the withdrawal
even more than before. That is why I am telling
myself: little, slow steps that are sustainable.”
VP_13
“… Valium® (diazepam) is the only thing that works
against Dormicum® (midazolam). Seresta® (oxazepam)
does not work. I have tried it. With this you are
equally on withdrawal, even worse. In here they
wanted to give me Seresta® (oxazepam) initially during
admission. That is where I said: ‘No way! Otherwise I
will just leave right now.’ Seresta® (oxazepam) just
does not work in me. I then told them several times
and then they said ‘O.K., then we will take Valium®
(diazepam)…’”
VP_30
“They switched to Valium® (diazepam) so that we
could do the withdrawal with Valium® (diazepam)
(instead of Xanax® (alprazolam)). They initially made
a calculation error, and I received far too little. One
morning I was almost collapsing, but one of the nurses
reacted very promptly. She gave me immediately the
drug. I then sat down, took it, and two minutes late I
was starting to feel better.”
VP_15
“…here in the inpatient unit, the first time, they were
trying it with Seroquel® (quetiapine). That is a
psychoactive drug, at first together with benzodiazepines,
just less of them combined with that psychoactive drug.
This (drug) did not show any effectiveness in me; it did
not work how it was supposed to do.”
VP_13
“…I drink a lot of ‘Withdrawal Tea’ (a nursing staff
mixture). I recommend that to everybody, I almost
cannot taste it any longer but it helps, very good, for
withdrawal, but today I think I will need more of
the ‘chemistry’ (is referring to prescribed
benzodiazepines)…”
VP_28
Longer time spent in inpatient treatment is better than
shorter
It was usual for study subjects to link a later relapse with
the amount of time they had spent in inpatient treat-
ment. Although many had experienced relapse days after
leaving several months of inpatient treatment, they fa-
vored long-term treatment approaches over shorter in-
terventions. In their search for these, some were even
willing to sacrifice their employment. While several
months of inpatient treatment were considered accept-
able, long-term inpatient treatment in specialized facil-
ities seemed not to be, since participants thought such
interventions would alter their personalities.
“And in the inpatient unit they withdrew me very
slowly. I think I was there for three months. This went
very well. And then I went for rehabilitation to another
hospital, were I stayed for another two-and-a-half
months… and then I was clean for almost five years.”
VP_12
“…Last time I was put under pressure by Dr. L. to get
discharged (from dual diagnosis inpatient unit),
because of my work position…But now I have
terminated my employment and called Dr. K.
(different inpatient unit) and asked him straightforward
if I would be under time pressure and get kicked out
after three weeks, or if I could do it in a way that I
wanted, that I felt well…”
VP_25
“…I am scared of the admission to a long-term inpatient
facility… How will it (therapy) change me? I am scared
that I would lose my personality there, and become an
entire ‘thing’ of psychiatry and psychology…”
VP_23
Abstinence is the goal
Participants entered treatment with the clear expectation
of complete BZD withdrawal and long-term abstinence.
However, some viewed their dependence as chronic,
after long-term use and frequent relapse, and were un-
sure if they could reach that goal.
“…I have no doubt I will make it to zero… (though) I do
take it for the last 15–20 years, always and always.”
VP_23
“…it is the question how realistic it is (to wean
BZDs off completely) and if I can achieve it, but at
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the moment I think I should try it and see how it
goes.”
VP_11
Discussion
Despite their clinical relevance, the reasons and motiva-
tions that high-dose BZD users decide to withdraw con-
tinue to be under-investigated. A recent study from
Australia among current BZD users with unknown dos-
ages identified “current lifestyle not okay” as the only
category for patients’ reason to stop [31]. Through our
study, we can add to this topic and report three major
interrelating themes that lead people to withdraw from
BZDs. First, participants described health concerns, most
commonly in the form of cognitive and physical impair-
ments. Second, subjects complained about the feeling of
being addicted and said that BZD use presented them
with a moral burden that limited their autonomy. Third
(and motives from this theme were frequently men-
tioned), individuals intended to discontinue their BZD
use because of external social factors. Participants were
often exposed to pressure or even coercion from their
relatives, or from institutional or governmental bodies,
to change their consumption pattern.
These motives are not significantly different from the
rationale provided by patients with other substance-use
disorders [32-34]. However, to the best of our know-
ledge, our study is the first that explores these motives
within a sample of high-dose BZD-dependent patients.
The themes that arose from the interviews conducted
among this group also reflect general and deeply held
views about discontinuation treatment and BZD with-
drawal. On one hand, participants had a long history of
abuse, had repeatedly attempted to stop taking this
medication, and expressed dissatisfaction, disappoint-
ment, and frustration with the outcome (withdrawal is
frequent and not very successful); on the other hand,
many wanted to continue to withdraw completely (ab-
stinence is the goal) and felt that it was well worth emo-
tional and social sacrifices (at home feels better than in
the clinic, but inpatient treatment is more effective and
longer inpatient treatment is better than shorter).
The majority of high-dose BZD-dependent individuals
indicated that BZD withdrawal symptoms were severe
and presented a wide variety of clinical symptoms, found
the duration of these symptoms difficult to anticipate,
and commonly experienced prolonged post-withdrawal
symptoms, as well (withdrawal is difficult and unpre-
dictable, with lots of complications). More specifically,
participants said that they had experienced chills, weak-
ness, headache, muscle pains, abdominal pain, nausea,
vomiting, diarrhea, tachycardia, dizziness, vision disorders,
irritability, nervousness, restlessness, difficulties sleeping,
symptoms of depression and anxiety, tickling sensations,
dissociation, complete loss of appetite, and epileptic sei-
zures, which are consistent with previous research on
BZD withdrawal [35,36].
Patients with a comorbid opioid dependence similarly
highlighted their perceived severity of symptoms and
repeatedly described BZD withdrawal as more difficult
than opioid withdrawal. This finding is in line with
a previous semi-quantitative study [37]. The present
study further demonstrates that many high-dose BZD-
dependent patients—whether or not they had been pre-
scribed BZDs by a physician—initially tried withdrawing
without seeking medical advice, usually by abruptly stop-
ping BZD usage in a home environment (the first time
happens at home). Results varied, but a recurrent re-
sponse in this study was the feeling that this had resulted
in perceived epileptic seizures [38-40]. Alarmingly, some
subjects viewed abrupt discontinuation as a very effective
form of treatment even after experiencing such symptoms.
In addition, even long-term high-dose users who had been
prescribed BZDs evidenced a variety of misconceptions
and lack of knowledge about the adverse effects of these
drugs. For example, some participants said that they were
surprised by their influenza-like withdrawal symptoms,
did not associate them with abrupt discontinuation of
BZDs, and had needed third parties to explain that they
might be experiencing symptoms of dependence. These
perceptions further illustrate the need to provide patients
with comprehensive information on the benefits and risks
of BZDs when initiating habit-forming treatment ap-
proaches, even if intended only for short-term use [41,42].
Participants favored gradual and long-term dosage ta-
pering to abrupt withdrawal (gradual tapering is better
than abrupt stopping, and few other things help). They
thereby confirmed the benefits of a treatment approach
that is in line with current recommendations and guide-
lines for therapeutic-dose users [12]. However, most par-
ticipants in this sample who had a history of mixing
BZDs were switched over at the time of admission to a
single BZD with an elimination half-life of 4–20 hours
(Lorazepam, Oxazepam), or, less frequently, to Diazepam
(20–100 hours), which was then tapered off. Subjects es-
pecially perceived this initial dose finding upon admis-
sion as very confusing, and often exhibited a limited
understanding of equivalent dosage calculations. As a
consequence, they subjectively associated more severe
withdrawal symptoms with different brand names rather
than with insufficient dosage. In some cases, the treating
physician’s choice of BZD for withdrawal contributed in
a major way to the participant’s decision to engage or
not to engage in treatment. We therefore recommend
that physicians consider this finding, since it further
underlines how subjective perceptions of treatment ap-
proaches contribute to compliant or non-compliant be-
havior, and thus to outcome in medical care [43,44].
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Limitations
Forty-one long-term, high-dose dependent patients in
Switzerland were studied. At the time of interview, the
majority were in inpatient treatment, so the authors do
not claim that the study is representative for all high-
dose dependent individuals. In addition, the sample re-
cruited for this study was self-selected, so we probably
missed individuals who felt uncomfortable discussing
their BZD use and are therefore likely to have missed
the views of those who felt especially sensitive about
their BZD dependence. Although interviews were con-
ducted outside the treatment setting and subjects were
assured that no information (except suicidal ideation)
would be made available to the treating physicians, some
participants might have believed that interviewers were
especially seeking their perceptions about the success of
their current discontinuation therapy, and they might
therefore have presented these perceptions. Despite
these limitations, however, this study is, to our know-
ledge, the first exploratory study conducted among the
subgroup of long-term high-dose dependent individuals
with a wide variety of comorbid mental disorders.
Conclusions
These findings provide deeper insights into the beliefs
and views of high-dose BZD-dependent individuals, es-
pecially in relation to the factors that motivate high-dose
BZD-dependent individuals to stop taking these medica-
tions, as well as how they experience withdrawal and
current treatment strategies. Future research needs to
address these important clinical questions within a larger
and more diverse subject sample.
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